Skip to main content

$5.19 0.12 (2.37%)

High

$5.29

Low

$5.12

Trades

1,945

Turnover

$3,576,754

Volume

686,116
30 June 2023 at 4:10pm
Register to track AVH and receive email alerts.

AVITA Medical Announces FDA Approval of RECELL for Vitiligo

StockBot

416,823 posts

AVH released this announcement to the ASX on 19 June 2023, 8:37. The announcement is marked as price sensitive, and is 3 page(s) in length and 195.88kb in size.

You can view all announcements from AVH and see how they appear on a price chart on the announcements page.

At the date of this announcement, AVH was 0.620% short sold according to ASIC data. It was ranked the 296th most shorted stock on the ASX. It remains ranked 348th as of the latest reported data (05 May 2025).

Other Recent Announcements from AVH
Notice under section 708A(5)(e) of the Corporations Act 30 June 2023, 12:01
Notification regarding unquoted securities - AVH 30 June 2023, 11:56
AVITA Medical Submits FDA PMA Supplement for RECELL GO 30 June 2023, 8:38
AVITA Medical Announces FDA Approval of RECELL for Vitiligo 19 June 2023, 8:37
AVITA Medical Appointment of Chief Financial Officer 16 June 2023, 8:44
Change of Director's Interest Notice - Suzanne Crowe 15 June 2023, 13:53
Change of Director's Interest Notice - Robert McNamara 15 June 2023, 13:51
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track AVH and receive email alerts.